LivaNova PLC (NASDAQ: LIVN)

LivaNova PLC is a leading global medical technology company that designs develops manufactures markets and sells products therapies and services aimed at improving patient outcomes. The company is headquartered in London England and its ordinary shares are listed on the Nasdaq under the ticker LIVN. LivaNova PLC pursues its mission to create ingenious medical solutions that ignite patient turnarounds.

The company generates revenue through the sale of cardiopulmonary and neuromodulation devices along with related services to healthcare providers worldwide. In the cardiopulmonary business revenue comes from products such as heart lung machines oxygenators autotransfusion systems perfusion tubing systems cannulae and associated accessories and from service contracts for equipment maintenance and technical support. In the neuromodulation business revenue is derived from the VNS Therapy System devices leads surgical accessories and from the aura6000 system for obstructive sleep apnea including ongoing service and support.

The company operates through the following segments: Cardiopulmonary and Neuromodulation. These segments are identified based on how management evaluates performance and allocates resources.

• Cardiopulmonary: This segment designs develops manufactures markets and sells cardiopulmonary products including heart lung machines oxygenators autotransfusion systems perfusion tubing systems cannulae and related accessories and provides services such as equipment maintenance technical support and training for healthcare professionals.

• Neuromodulation: This segment designs develops manufactures markets and sells devices that deliver neuromodulation therapy for treating drug resistant epilepsy and treatment resistant depression including the VNS Therapy System leads surgical accessories and programming tools and also develops the aura6000 system for obstructive sleep apnea which stimulates the hypoglossal nerve to keep the airway open during sleep.

LivaNova PLC holds a strong position in the global medical device market competing with major players such as Terumo Medical Corporation Maquet Medical Systems Medtronic plc Haemonetics Corporation Spectrum Medical Limited and NeuroPace Inc. The company differentiates itself through a focus on innovation clinical evidence and a broad portfolio that addresses critical needs in cardiac surgery and neurological therapy. Its competitive advantages include proprietary technology strong relationships with healthcare providers and a commitment to quality and regulatory compliance.

The company serves a diverse customer base that includes perfusionists neurologists neurosurgeons other healthcare professionals hospitals and other medical institutions and healthcare providers worldwide. In cardiopulmonary the main customers are hospital perfusion teams and surgical departments that perform coronary artery bypass valve surgery and other cardiac procedures. In neuromodulation the primary customers are neurologists neurosurgeons and epilepsy treatment centers that implant vagus nerve stimulation devices and sleep specialists who treat obstructive sleep apnea.